Oral hormonal therapy as treatment option for abnormal uterine bleeding

References

• Rodriguez MB, Dias S, Jordan V, et al. Interventions for heavy menstrual bleeding; overview of cochrane reviews and network meta‐analysis. Cochrane Database Syst Rev. 2022;5(5):CD013180. doi: 10.1002/14651858.CD013180.pub2.
   PubMedGoogle Scholar
• Graziottin A. The shorter, the better: a review of the evidence for a shorter contraceptive hormone-free interval. Eur J Contracept Reprod Health Care. 2016;21(2):93–105. doi: 10.3109/13625187.2015.1077380.
   PubMed Web of Science ®Google Scholar
• Liu Z, Doan QV, Blumenthal P, et al. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health. 2007;10(3):183–194. doi: 10.1111/j.1524-4733.2007.00168.x.
   PubMed Web of Science ®Google Scholar
• Munro MG, Critchley HOD, Fraser IS, the FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393–408. doi: 10.1002/ijgo.12666.
   PubMed Web of Science ®Google Scholar
• Jewson M, Purohit P, Lumsden MA. Progesterone and abnormal uterine bleeding/menstrual disorders. Best Pract Res Clin Obstet Gynaecol. 2020;69:62–73. doi: 10.1016/j.bpobgyn.2020.05.004.
   PubMed Web of Science ®Google Scholar
• Marnach ML, Laughlin-Tommaso SK. Evaluation and management of abnormal uterine bleeding. Mayo Clin Proc. 2019;94(2):326–335. doi: 10.1016/j.mayocp.2018.12.012.
   PubMed Web of Science ®Google Scholar
• ACOG Committee on Practice Bulletins–Gynecology. American college of obstetricians and gynecologists. ACOG practice bulletin: management of anovulatory bleeding. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2001;72(3):263–271.
   PubMed Web of Science ®Google Scholar
• Committee on Practice Bulletins—Gynecology. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol. 2012;120(1):197–206.
   PubMedGoogle Scholar
• Fraser IS, Critchley HOD, Broder M, et al. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med. 2011;29(5):383–390. doi: 10.1055/s-0031-1287662.
   PubMed Web of Science ®Google Scholar
• Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. BJOG. 2000;107(3):320–322. doi: 10.1111/j.1471-0528.2000.tb13225.x.
   PubMedGoogle Scholar
• Spence M, de Repentigny K, Bowman M, et al. Validation of the pictorial blood loss assessment chart using modern sanitary products. Haemoph Off J World Fed Hemoph. 2021;27(5):e632–e635.
   PubMed Web of Science ®Google Scholar
• Khafaga A, Goldstein SR. Abnormal uterine bleeding. Obstet Gynecol Clin North Am. 2019;46(4):595–605. doi: 10.1016/j.ogc.2019.07.001.
   PubMed Web of Science ®Google Scholar
• Ely JW, Kennedy CM, Clark EC, et al. Abnormal uterine bleeding: a management algorithm. J Am Board Fam Med. 2006;19(6):590–602. doi: 10.3122/jabfm.19.6.590.
   PubMed Web of Science ®Google Scholar
• Kabra R, Fisher M. Abnormal uterine bleeding in adolescents. Curr Probl Pediatr Adolesc Health Care. 2022;52(5):101185. doi: 10.1016/j.cppeds.2022.101185.
   PubMed Web of Science ®Google Scholar
• Sweet MG, Schmidt-Dalton TA, Weiss PM, et al. Evaluation and management of abnormal uterine bleeding in premenopausal women. Am Fam Physician. 2012;85(1):35–43.
   PubMed Web of Science ®Google Scholar
• Wheeler KC, Goldstein SR. Transvaginal ultrasound for the diagnosis of abnormal uterine bleeding. Clin Obstet Gynecol. 2017;60(1):11–17. doi: 10.1097/GRF.0000000000000257.
   PubMed Web of Science ®Google Scholar
• Hurskainen R, Grenman S, Komi I, et al. Diagnosis and treatment of menorrhagia. Acta Obstet Gynecol Scand. 2007;86(6):749–757. doi: 10.1080/00016340701415400.
   PubMed Web of Science ®Google Scholar
• Heavy menstrual bleeding: assessment and management. National Institute for Health and Care Excellence (NICE): London. 2021 http://www.ncbi.nlm.nih.gov/books/NBK493300/. (accessed 23 Nov 2022).
   Google Scholar
• ESHRE Capri Workshop Group. Intrauterine devices and intrauterine systems. Hum Reprod Update. 2008;14(3):197–208.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Shapiro H, Lukkari-Lax E, et al. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can. 2009;31(4):340–347. doi: 10.1016/S1701-2163(16)34151-2.
   PubMedGoogle Scholar
• Shaaban MM, Zakherah MS, El-Nashar SA, et al. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception. 2011;83(1):48–54. doi: 10.1016/j.contraception.2010.06.011.
   PubMed Web of Science ®Google Scholar
• Sayed GH, Zakherah MS, El-Nashar SA, et al. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet. 2011;112(2):126–130. doi: 10.1016/j.ijgo.2010.08.009.
   PubMed Web of Science ®Google Scholar
• Matteson KA, Valcin J, Raker CA, et al. A randomized trial comparing the 52-mg levonorgestrel system with combination oral contraceptives for treatment of heavy menstrual bleeding. Am J Obstet Gynecol. 2023;S0002-9378(23):00521–00525. doi: 10.1016/j.ajog.2023.07.049.
   Google Scholar
• Uhm S, Perriera L. Hormonal contraception as treatment for heavy menstrual bleeding: a systematic review. Clin Obstet Gynecol. 2014;57(4):694–717. doi: 10.1097/GRF.0000000000000061.
   PubMed Web of Science ®Google Scholar
• Bofill Rodriguez M, Lethaby A, Low C, et al. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;8(8):CD001016.
   PubMedGoogle Scholar
• Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol. 1998;105(6):592–598. doi: 10.1111/j.1471-0528.1998.tb10172.x.
   PubMedGoogle Scholar
• Küçük T, Ertan K. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. Clin Exp Obstet Gynecol. 2008;35(1):57–60.
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Bissonnette F, Monteiro I, et al. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(3):625–632. doi: 10.1097/AOG.0b013e3181ec622b.
   PubMed Web of Science ®Google Scholar
• Medical Eligibility Criteria for Contraceptive Use. 5th ed. Geneva: World Health Organization; 2015. http://www.ncbi.nlm.nih.gov/books/NBK321151/
   Google Scholar
• Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2016;2016(1):CD003855.
   PubMedGoogle Scholar
• Hall AM, Kutler BA. Intrauterine contraception in nulliparous women: a prospective survey. J Fam Plann Reprod Health Care. 2016;42(1):36–42. doi: 10.1136/jfprhc-2014-101046.
   PubMedGoogle Scholar
• Bradley LD, Gueye N-A. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. 2016;214(1):31–44. doi: 10.1016/j.ajog.2015.07.044.
   PubMed Web of Science ®Google Scholar
• Kadir RA, Lukes AS, Kouides PA, et al. Management of excessive menstrual bleeding in women with hemostatic disorders. Fertil Steril. 2005;84(5):1352–1359. doi: 10.1016/j.fertnstert.2005.04.062.
   PubMed Web of Science ®Google Scholar
• López Bernal A, Buckley S, Rees CM, et al. Meclofenamate inhibits prostaglandin E binding and adenylyl cyclase activation in human myometrium. J Endocrinol. 1991;129(3):439–445. doi: 10.1677/joe.0.1290439.
   PubMed Web of Science ®Google Scholar
• Levy-Zauberman Y, Pourcelot A-G, Capmas P, et al. Update on the management of abnormal uterine bleeding. J Gynecol Obstet Hum Reprod. 2017;46(8):613–622. doi: 10.1016/j.jogoh.2017.07.005.
   PubMed Web of Science ®Google Scholar
• Bryant-Smith AC, Lethaby A, Farquhar C, et al. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2018;4(4):CD000249.
   PubMedGoogle Scholar
• Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;9(9):CD000400.
   PubMedGoogle Scholar
• Pinkerton JV. Pharmacological therapy for abnormal uterine bleeding. Menopause. 2011;18(4):453–461. doi: 10.1097/gme.0b013e318212499c.
   PubMed Web of Science ®Google Scholar
• Matteson KA, Rahn DD, Wheeler TL, et al. Nonsurgical management of heavy menstrual bleeding: a systematic review. Obstet Gynecol. 2013;121(3):632–643. doi: 10.1097/AOG.0b013e3182839e0e.
   PubMed Web of Science ®Google Scholar
• Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril. 2018;109(3):398–405. doi: 10.1016/j.fertnstert.2018.01.013.
   PubMed Web of Science ®Google Scholar
• Nelson AL, Teal SB. Medical therapies for chronic menorrhagia. Obstet Gynecol Surv. 2007;62(4):272–281. doi: 10.1097/01.ogx.0000259228.70277.6f.
   PubMed Web of Science ®Google Scholar
• Chiara Del Savio M, De Fata R, Facchinetti F, et al. Drospirenone 4 mg-only pill (DOP) in 24 + 4 regimen: a new option for oral contraception. Expert Rev Clin Pharmacol. 2020;13(7):685–694. doi: 10.1080/17512433.2020.1783247.
   PubMed Web of Science ®Google Scholar
• Archer DF, Mansour D, Foidart J-M. Bleeding patterns of oral contraceptives with a cyclic dosing regimen: an overview. J Clin Med. 2022;11(15):4634. doi: 10.3390/jcm11154634.
   PubMed Web of Science ®Google Scholar
• Abu Hashim H. Medical treatment of idiopathic heavy menstrual bleeding. What is new? An evidence based approach. Arch Gynecol Obstet. 2013;287(2):251–260. doi: 10.1007/s00404-012-2605-y.
   PubMed Web of Science ®Google Scholar
• A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Collaborative study group on the desogestrel-containing progestogen-only pill. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 1998;3(4):169–178.
   PubMedGoogle Scholar
• Lello S. Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. Drugs. 2010;70(5):541–559. doi: 10.2165/11532130-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Marret H, Fauconnier A, Chabbert-Buffet N, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol. 2010;152(2):133–137. doi: 10.1016/j.ejogrb.2010.07.016.
   PubMed Web of Science ®Google Scholar
• Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol. 2013;122(1):176–185.
   PubMedGoogle Scholar
• Bitzer J, Heikinheimo O, Nelson AL, et al. Medical management of heavy menstrual bleeding: a comprehensive review of the literature. Obstet Gynecol Surv. 2015;70(2):115–130. doi: 10.1097/OGX.0000000000000155.
   PubMed Web of Science ®Google Scholar
• Grandi G, Del Savio MC, Tassi A, et al. Postpartum contraception: a matter of guidelines. Int J Gynaecol Obstet. 2023;0:1–10. doi: 10.1002/ijgo.14928.
   Google Scholar
• Singh RH, Blumenthal P. Hormonal management of abnormal uterine bleeding. Clin Obstet Gynecol. 2005;48(2):337–352. doi: 10.1097/01.grf.0000159540.11974.17.
   PubMed Web of Science ®Google Scholar
• De Leo V, Musacchio MC, Cappelli V, et al. Hormonal contraceptives: pharmacology tailored to women’s health. Hum Reprod Update. 2016;22(5):634–646. doi: 10.1093/humupd/dmw016.
   PubMed Web of Science ®Google Scholar
• Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021;103(4):213–221. doi: 10.1016/j.contraception.2021.01.001.
   PubMed Web of Science ®Google Scholar
• Hickey M, Higham JM, Fraser I. Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev. 2012;2012(9):CD001895. doi: 10.1002/14651858.CD001895.pub3.
   PubMedGoogle Scholar
• Larsson G, Milsom I, Lindstedt G, et al. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception. 1992;46(4):327–334. doi: 10.1016/0010-7824(92)90095-b.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Wise MR, Weterings MA, et al. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;2(2):CD000154.
   PubMedGoogle Scholar
• Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol. 2001;98(5 Pt 1):771–778. doi: 10.1097/00006250-200111000-00011.
   PubMed Web of Science ®Google Scholar
• Fraser IS, Römer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind phase III trial. Hum Reprod. 2011;26(10):2698–2708. doi: 10.1093/humrep/der224.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Parke S, Mellinger U, et al. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol. 2011;117(4):777–787. doi: 10.1097/AOG.0b013e3182118ac3.
   PubMed Web of Science ®Google Scholar
• Fraser IS, Parke S, Mellinger U, et al. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2011;16(4):258–269. doi: 10.3109/13625187.2011.591456.
   PubMed Web of Science ®Google Scholar
• Ahrendt H-J, Makalová D, Parke S, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80(5):436–444. doi: 10.1016/j.contraception.2009.03.018.
   PubMed Web of Science ®Google Scholar
• Al-Hendy A, Lukes AS, Poindexter AN, et al. Long-term relugolix combination therapy for symptomatic uterine leiomyomas. Obstet Gynecol. 2022;140(6):920–930. doi: 10.1097/AOG.0000000000004988.
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382(4):328–340. doi: 10.1056/NEJMoa1904351.
   PubMed Web of Science ®Google Scholar
• Donnez J, Taylor HS, Stewart EA, et al. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Lancet. 2022;400(10356):896–907. doi: 10.1016/S0140-6736(22)01475-1.
   PubMed Web of Science ®Google Scholar